The Medical Letter on Drugs and Therapeutics
Canakinumab (Ilaris) for Systemic Juvenile Idiopathic Arthritis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the interleukin-1 (IL-1) beta inhibitor canakinumab (Ilaris – Novartis) for treatment of systemic juvenile idiopathic arthritis (sJIA; formerly called juvenile rheumatoid arthritis or Still’s disease) in children ≥2 years old. Canakinumab was approved earlier for treatment of cryopyrin-associated periodic syndromes (CAPS). Tocilizumab (Actemra), an interleukin-6 (IL-6) inhibitor that has been available since 2010 for treatment of rheumatoid arthritis in adults,1 was also recently approved by the FDA for sJIA. Canakinumab is the only IL-1 inhibitor approved for this indication.

THE DISEASE — sJIA is a severe sub-type of juvenile idiopathic arthritis characterized by daily high fever, evanescent maculopapular rash, and inflammatory polyarthritis. Complications of the disease include macrophage activation syndrome (MAS), which can be ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Canakinumab (Ilaris) for Systemic Juvenile Idiopathic Arthritis
Article code: 1423a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian